Clinical Trials

55 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06492759 2026-04-17

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

29 enrolled

Triple Negative Breast Neoplasms

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

120 enrolled

Triple Negative Breast Neoplasms

NCT02876107 2026-04-15

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

42 enrolled

Breast Neoplasms, Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07045311 2026-04-15

JS207 Combination Therapy in Triple-negative Breast Cancer

80 enrolled

Triple Negative Breast Neoplasms

NCT04677816 2026-04-14

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

50 enrolled

Vitamin D Deficiency, Triple Negative Breast Neoplasms

NCT07528768 2026-04-14

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

750 enrolled

Triple Negative Breast Neoplasms

NCT04768426 2026-04-13

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

40 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07069595 2026-04-13

PREDICT-RD

78 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07340541 2026-04-13

EVOLVE-BDT

700 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06649331 2026-04-08

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

160 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06604858 2026-04-07

TELESCOPE

31 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07078604 2026-04-07

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

20 enrolled

Triple Negative Breast Neoplasms

NCT05660083 2026-04-03

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

36 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07509515 2026-04-03

QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.

60 enrolled

Triple Negative Breast Neoplasms

NCT04877821 2026-04-02

NeoSACT

29 enrolled

Triple Negative Breast Neoplasms

NCT06358573 2026-04-02

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

61 enrolled

Triple Negative Breast Neoplasms

NCT07017673 2026-04-02

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

34 enrolled

Triple Negative Breast Neoplasms

NCT06365788 2026-04-01

ABBICAR

53 enrolled

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

NCT06768931 2026-04-01

Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer

192 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01525966 2026-03-30

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

67 enrolled 12 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02422498 2026-03-24

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

49 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT06831955 2026-03-20

LESLIE

356 enrolled

Triple Negative Breast Neoplasms

NCT07394387 2026-03-19

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

39 enrolled

Triple Negative Breast Neoplasms

NCT05340413 2026-03-16

RADIOLA

65 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT07471815 2026-03-13

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

30 enrolled

Triple Negative Breast Neoplasms

NCT07466303 2026-03-12

Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer

84 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07457359 2026-03-09

NEOTRIO-2

18 enrolled

Triple Negative Breast Neoplasms

NCT07458113 2026-03-09

BERLIN

20 enrolled

BreastCNS

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT07458204 2026-03-09

EPPIL

760 enrolled

Recurrence, Triple Negative Breast Neoplasms

NCT03941730 2026-03-05

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

8 enrolled 9 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06318897 2026-03-04

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

28 enrolled

Triple Negative Breast Neoplasms

NCT07276880 2026-03-03

P-RAD(+)TN-DCT

32 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06434064 2026-03-02

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

30 enrolled

Triple Negative Breast Neoplasms

NCT07342283 2026-03-02

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

30 enrolled

Triple Negative Breast Neoplasms

NCT07441512 2026-03-02

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

26 enrolled

Triple Negative Breast Neoplasms

NCT03808337 2026-02-27

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

145 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT04468061 2026-02-27

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

110 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT06802757 2026-02-25

PRISM-TNBC

72 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06976944 2026-02-23

PRELUDE

44 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07419880 2026-02-19

RECLAIM

46 enrolled

Triple Negative Breast Neoplasms

NCT02530489 2026-02-17

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

37 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT04683679 2026-02-17

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

34 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05741164 2026-02-17

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

37 enrolled

Triple Negative Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

85 enrolled

Triple Negative Breast Neoplasms

NCT07413601 2026-02-17

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

78 enrolled

Triple Negative Breast Neoplasms

NCT03301350 2026-02-13

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

29 enrolled 15 charts